Janux Therapeutics, Inc. experienced a net loss of $23.5 million in Q1 2025, an increase from $14.8 million in Q1 2024. This was primarily due to a significant increase in total operating expenses, particularly in research and development, and a decrease in collaboration revenue. However, the company saw a substantial rise in other income, mainly from interest income.

Janux Therapeutics had an exceptional year in 2024, demonstrating substantial clinical activity with JANX007 and significantly strengthening its financial position with $1.03 billion in cash, cash equivalents, and short-term investments. The company reported a net loss of $20.2 million for the quarter, with research and development expenses increasing to $20.8 million.

Janux Therapeutics reported a net loss of $28.1 million for the third quarter of 2024, with cash and cash equivalents and short-term investments totaling $658.0 million. The company is focused on enrolling participants in clinical trials for JANX007 and JANX008 and anticipates providing an update on the JANX007 program by year end.

Janux Therapeutics reported a net loss of $6.0 million for the second quarter of 2024. The company's cash and cash equivalents and short-term investments totaled $646.3 million as of June 30, 2024. They also received a $7.5 million milestone payment from Merck.

Janux Therapeutics reported a net loss of $14.8 million for the first quarter of 2024. The company's cash and cash equivalents and short-term investments totaled $651.8 million as of March 31, 2024. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors.

Janux Therapeutics reported a net loss of $11.8 million for the quarter and cash, cash equivalents, and short-term investments of $344.0 million as of December 31, 2023.

Janux Therapeutics reported $349.7 million in cash, cash equivalents, and short-term investments at the end of the third quarter 2023. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors. A net loss of $11.6 million was reported for the quarter ended September 30, 2023.

Janux Therapeutics reported positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer, strengthened their management team, and had $303.3 million in cash, cash equivalents, and short-term investments at the end of the second quarter 2023. They further strengthened their balance sheet with an approximately $60 million offering in July.

Janux Therapeutics reported first quarter 2023 financial results, including cash and cash equivalents and short-term investments of $316.9 million. The company's research and development expenses were $15.9 million, and general and administrative expenses were $6.5 million, resulting in a net loss of $17.5 million.

Janux Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022. The company's lead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients and Janux received FDA clearance for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008).

Janux Therapeutics reported a net loss of $16.7 million for the third quarter of 2022, with cash and cash equivalents and short-term investments totaling $338.8 million. The company dosed the first patient with JANX007 in a Phase 1 clinical trial and anticipates submitting an IND for EGFR-TRACTr (JANX008) in the second half of 2022.

Janux Therapeutics reported second quarter 2022 financial results, including cash and cash equivalents and short-term investments of $354.3 million. The FDA cleared the IND application for JANX007, and the IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022.

Janux Therapeutics reported a net loss of $13.4 million for the first quarter of 2022. The company's cash and cash equivalents and short-term investments totaled $361.2 million as of March 31, 2022. Janux continues to advance its pipeline of immunotherapies, with IND applications planned for JANX007 and JANX008 in 2022 and TROP2-TRACTr and PD-L1xCD28 TRACIr programs in 2023.

Janux Therapeutics reported cash, cash equivalents and short-term investments of $375.0 million. Research and development expenses were $11.2 million. Net loss was $13.4 million for the quarter.

Janux Therapeutics reported $387.5 million in cash and cash equivalents and short-term investments. The company is on track to submit IND filings for two programs in 2022. Net loss was $10.8 million for the quarter ended September 30, 2021.

Janux Therapeutics reported a net loss of $6.2 million for the second quarter of 2021. The company successfully completed a $222.9 million IPO in June, bringing total funds raised in the quarter to $347.9 million. Research and development expenses increased to $4.7 million, reflecting the development of the TRACTr platform technology and programs.